Recent News

• 05.13.2026 - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
• 04.15.2026 - Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
• 03.23.2026 - Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
• 03.03.2026 - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Recent Filings

• 05.13.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 8-K Current report
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.28.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.15.2026 - 8-K Current report
• 04.15.2026 - EX-99.1 EX-99.1
• 04.14.2026 - DEF 14A Other definitive proxy statements
• 04.14.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.13.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.23.2026 - 8-K Current report